ISUPREL
LOE ApproachingNDARECTAL, SUBLINGUALTABLET
Approved
Feb 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISUPREL is a small-molecule sympathomimetic amine approved in 1948 for rectal and sublingual administration as a tablet. The exact indications are not specified in available data, but historically it has been used for bronchospasm and cardiac arrhythmias. Its mechanism of action involves beta-adrenergic stimulation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature brand with likely declining team support and transition planning underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a mature product with minimal hiring. Roles available are primarily defensive—protecting market share during LOE transition rather than growth-oriented positions. Career growth on this product is limited; professionals typically move to newer pipeline assets.
Brand ManagerProduct Manager
Worked on ISUPREL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.